Journal List > Korean J Gastroenterol > v.72(3) > 1101289

Kim and Lee: Multiple Pyoderma Gangrenosum in Ulcerative Colitis

Figures and Tables

Fig. 1

Abdominal computed tomography scan showed wall thickening of sigmoid colon and rectum (white arrows).

kjg-72-155-g001
Fig. 2

Colonoscopy showed diffuse hyperemic mucosa with aphthous ulcers and mucosal edema and hemorrhages at sigmoid colon (A) and multiple deep ulcers with exudate at the rectum (B).

kjg-72-155-g002
Fig. 3

Rectum biopsy showed lymphoplasmacytic infiltration, ulceration, and a few distorted crypts (H&E, ×10).

kjg-72-155-g003
Fig. 4

On admission day 2, the patient presented painful nodules and erythematous lesions on his right knee (A) and left foot (B) that progressed rapidly to irregular ulcers.

kjg-72-155-g004
Fig. 5

Biopsy specimen from the ulcer of the right knee showed granulation tissue, lymphocyte infiltration, and abscess formation (H&E, ×100) (A) and abundant neutrophilic infiltration, resulting in abscess formation (H&E, ×200) (B).

kjg-72-155-g005
Fig. 6

Incision and drainage of skin lesions of the left thumb (A), foot (B), and right knee (C) was performed.

kjg-72-155-g006
Fig. 7

Healing ulcers with crust and hyperpigmentation on the left thumb (A), foot (B), and right knee (C) after systemic steroid therapy.

kjg-72-155-g007
Fig. 8

Follow up sigmoidoscopy after treatment shows ulcer scar and pseudo-polyps at sigmoid colon and rectum.

kjg-72-155-g008

Notes

Financial support This work was supported by the 2016 Yeungnam University Research Grant.

Conflict of interest None.

References

1. Lee JI, Park HJ, Lee JY, Cho BK. A case of pyoderma gangrenosum with ulcerative colitis treated with mesalazine. Ann Dermatol. 2010; 22:422–425.
crossref
2. Binus AM, Qureshi AA, Li VW, Winterfield LS. Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients. Br J Dermatol. 2011; 165:1244–1250.
crossref
3. Powell FC, Su WP, Perry HO. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol. 1996; 34:395–409. quiz 410-412.
crossref
4. Mlika RB, Riahi I, Fenniche S, et al. Pyoderma gangrenosum: a report of 21 cases. Int J Dermatol. 2002; 41:65–68.
crossref
5. Greuter T, Navarini A, Vavricka SR. Skin manifestations of inflammatory bowel disease. Clin Rev Allergy Immunol. 2017; 53:413–427.
crossref
6. Ahn C, Negus D, Huang W. Pyoderma gangrenosum: a review of pathogenesis and treatment. Expert Rev Clin Immunol. 2018; 14:225–233.
crossref
7. Byeon YM, Lee J, Lee SJ, et al. Peritonsillar involvement in pyoderma gangrenosum associated with ulcerative colitis. Intest Res. 2014; 12:153–156.
crossref
8. Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2015; 21:1982–1992.
crossref
9. Herberger K, Dissemond J, Hohaus K, Schaller J, Anastasiadou Z, Augustin M. Treatment of pyoderma gangrenosum: retrospective multicentre analysis of 121 patients. Br J Dermatol. 2016; 175:1070–1072.
crossref
10. Ormerod AD, Thomas KS, Craig FE, et al. Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. BMJ. 2015; 350:h2958.
crossref
11. Brooklyn TN, Dunnill MG, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006; 55:505–509.
crossref
12. Al Rajabi W, Venturini M, Sala R, Calzavara-Pinton P. Wegener's granulomatosis of the penis: genital presentation of systemic disease. Dermatology. 2006; 212:370–372.
crossref
TOOLS
ORCID iDs

Si Hyung Lee
https://orcid.org/0000-0001-7221-7506

Similar articles